RhumbLine Advisers’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.3M | Buy |
56,800
+64
| +0.1% | +$12.7K | 0.01% | 999 |
|
|
2025
Q4 | $10.7M | Sell |
56,736
-2,686
| -5% | -$516K | 0.01% | 1029 |
|
|
2025
Q3 | $10.5M | Sell |
59,422
-86
| -0.1% | -$12.8K | 0.01% | 1061 |
|
|
2025
Q2 | $6.76M | Buy |
59,508
+2,052
| +4% | +$219K | 0.01% | 1256 |
|
|
2025
Q1 | $6.04M | Sell |
57,456
-1,989
| -3% | -$225K | 0.01% | 1257 |
|
|
2024
Q4 | $6.37M | Sell |
59,445
-575
| -1% | -$65K | 0.01% | 1300 |
|
|
2024
Q3 | $6.01M | Sell |
60,020
-1,312
| -2% | -$132K | 0.01% | 1331 |
|
|
2024
Q2 | $5.17M | Buy |
61,332
+1,077
| +2% | +$85.7K | ﹤0.01% | 1380 |
|
|
2024
Q1 | $4.4M | Buy |
60,255
+730
| +1% | +$53.8K | ﹤0.01% | 1478 |
|
|
2023
Q4 | $4.25M | Buy |
59,525
+2,398
| +4% | +$142K | ﹤0.01% | 1518 |
|
|
2023
Q3 | $3.42M | Buy |
57,127
+1,628
| +3% | +$107K | ﹤0.01% | 1565 |
|
|
2023
Q2 | $4M | Buy |
55,499
+2,458
| +5% | +$184K | ﹤0.01% | 1513 |
|
|
2023
Q1 | $3.9M | Buy |
53,041
+2,342
| +5% | +$166K | ﹤0.01% | 1454 |
|
|
2022
Q4 | $3.39M | Sell |
50,699
-27,058
| -35% | -$1.76M | ﹤0.01% | 1515 |
|
|
2022
Q3 | $4.18M | Buy |
77,757
+1,063
| +1% | +$62.5K | 0.01% | 1340 |
|
|
2022
Q2 | $4.27M | Buy |
76,694
+2,913
| +4% | +$165K | 0.01% | 1331 |
|
|
2022
Q1 | $5.18M | Buy |
73,781
+1,641
| +2% | +$119K | 0.01% | 1291 |
|
|
2021
Q4 | $6.95M | Sell |
72,140
-1,936
| -3% | -$179K | 0.01% | 1182 |
|
|
2021
Q3 | $6.44M | Sell |
74,076
-7,071
| -9% | -$547K | 0.01% | 1198 |
|
|
2021
Q2 | $6.64M | Buy |
81,147
+8,186
| +11% | +$681K | 0.01% | 1270 |
|
|
2021
Q1 | $6.94M | Sell |
72,961
-466
| -0.6% | -$44.1K | 0.01% | 1218 |
|
|
2020
Q4 | $4.55M | Buy |
73,427
+26
| +0% | +$1.48K | 0.01% | 1407 |
|
|
2020
Q3 | $4.37M | Sell |
73,401
-14,264
| -16% | -$973K | 0.01% | 1251 |
|
|
2020
Q2 | $6.12M | Sell |
87,665
-12,337
| -12% | -$782K | 0.01% | 1079 |
|
|
2020
Q1 | $4.54M | Sell |
100,002
-546
| -0.5% | -$30.9K | 0.01% | 1077 |
|
|
2019
Q4 | $6.54M | Sell |
100,548
-4,899
| -5% | -$327K | 0.01% | 1093 |
|
|
2019
Q3 | $6.55M | Sell |
105,447
-981
| -0.9% | -$61.6K | 0.01% | 1039 |
|
|
2019
Q2 | $7.58M | Sell |
106,428
-1,308
| -1% | -$96.3K | 0.01% | 942 |
|
|
2019
Q1 | $8.45M | Sell |
107,736
-612
| -0.6% | -$46.4K | 0.02% | 860 |
|
|
2018
Q4 | $9.17M | Buy |
108,348
+25,511
| +31% | +$2.72M | 0.02% | 758 |
|
|
2018
Q3 | $14.2M | Sell |
82,837
-3,000
| -3% | -$452K | 0.03% | 543 |
|
|
2018
Q2 | $11.1M | Buy |
85,837
+3,550
| +4% | +$396K | 0.02% | 634 |
|
|
2018
Q1 | $8.48M | Buy |
82,287
+999
| +1% | +$98.8K | 0.02% | 733 |
|
|
2017
Q4 | $6.94M | Buy |
81,288
+11,529
| +17% | +$999K | 0.01% | 872 |
|
|
2017
Q3 | $5.92M | Buy |
69,759
+4,743
| +7% | +$376K | 0.01% | 938 |
|
|
2017
Q2 | $4.92M | Buy |
65,016
+930
| +1% | +$65.1K | 0.01% | 1009 |
|
|
2017
Q1 | $4.23M | Buy |
64,086
+16,815
| +36% | +$1.11M | 0.01% | 1107 |
|
|
2016
Q4 | $3M | Buy |
47,271
+2,932
| +7% | +$185K | 0.01% | 1210 |
|
|
2016
Q3 | $2.82M | Buy |
44,339
+2,770
| +7% | +$203K | 0.01% | 1192 |
|
|
2016
Q2 | $3.09M | Buy |
41,569
+2,252
| +6% | +$167K | 0.01% | 1087 |
|
|
2016
Q1 | $2.63M | Buy |
39,317
+754
| +2% | +$45.8K | 0.01% | 1199 |
|
|
2015
Q4 | $2.61M | Buy |
38,563
+4,562
| +13% | +$282K | 0.01% | 1184 |
|
|
2015
Q3 | $1.82M | Buy |
34,001
+899
| +3% | +$54.5K | 0.01% | 1379 |
|
|
2015
Q2 | $2.08M | Sell |
33,102
-4,726
| -12% | -$258K | 0.01% | 1378 |
|
|
2015
Q1 | $1.82M | Buy |
37,828
+3,759
| +11% | +$144K | 0.01% | 1463 |
|
|
2014
Q4 | $1.13M | Sell |
34,069
-1,162
| -3% | -$37.8K | ﹤0.01% | 1718 |
|
|
2014
Q3 | $1.03M | Sell |
35,231
-2,164
| -6% | -$71.8K | ﹤0.01% | 1737 |
|
|
2014
Q2 | $1.45M | Buy |
37,395
+2,860
| +8% | +$116K | ﹤0.01% | 1582 |
|
|
2014
Q1 | $1.45M | Sell |
34,535
-1,268
| -4% | -$52.9K | ﹤0.01% | 1559 |
|
|
2013
Q4 | $1.18M | Buy |
35,803
+7,117
| +25% | +$232K | ﹤0.01% | 1695 |
|
|
2013
Q3 | $774K | Sell |
28,686
-195
| -0.7% | -$5.49K | ﹤0.01% | 1948 |
|
|
2013
Q2 | $674K | Buy |
+28,881
| New | +$519K | ﹤0.01% | 2040 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
RhumbLine Advisers's LGND Position: Q1 2026 in Review
RhumbLine Advisers increased its Ligand Pharmaceuticals (LGND) stake by 0.11% in Q1 2026, buying an estimated $12.7K and bringing the position to 56,800 shares worth $11.3M. The position accounts for 0.01% of the portfolio, ranked #999.
RhumbLine Advisers first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.2M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- RhumbLine Advisers held 56,800 shares of Ligand Pharmaceuticals worth $11.3M as of Q1 2026.
- RhumbLine Advisers bought 64 Ligand Pharmaceuticals shares in Q1 2026, an estimated $12.7K.
- Ligand Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #999 holding.
- RhumbLine Advisers first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- RhumbLine Advisers's Ligand Pharmaceuticals position peaked at $14.2M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.